Side effects of semaglutide 14mg tablets: what to expect

Why does the 14mg dose exist, and which medicine actually contains it?

This is the question our prescribers hear most often when people arrive having searched for "semaglutide 14mg tablets side effects". Semaglutide at 3mg, 7mg and 14mg refers to Rybelsus, approved in the UK for adults with type 2 diabetes. It is not licensed for weight management. The dose escalation for Rybelsus starts at 3mg for one month, moves to 7mg, then to 14mg as the maintenance dose. If you have been prescribed Rybelsus and want to understand what to expect, our guide to semaglutide tablets side effects covers the full picture alongside the NHS semaglutide medicines page, which remains the clearest patient-level reference available.

Wegovy tablets, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management, follow a completely different schedule: 1.5mg, 4mg, 9mg and 25mg maintenance. The side-effect profiles of both share a common thread because the active ingredient is the same, but you should always refer to the patient information leaflet for the specific product you have been dispensed. A useful overview of how the two formulations sit within the semaglutide family is on our semaglutide tablets guide.

If someone is prescribed Rybelsus and is later assessed for weight management treatment, switching to a licensed weight-management medicine is a clinical conversation, not something to self-manage.

What are the common side effects shared across oral semaglutide tablets?

Because both Rybelsus and Wegovy tablets deliver semaglutide, their side-effect patterns overlap substantially. The most frequently reported effects are gastrointestinal. Nausea sits at the top of the list; many people also experience vomiting, diarrhoea, constipation, abdominal discomfort, burping and reflux. In the OASIS 4 phase-3 trial of Wegovy tablets, around 74% of participants taking oral semaglutide reported a GI side effect at some point, compared with 42% on placebo. The MHRA-approved electronic Medicines Compendium (eMC) holds the full SmPC for each product, including a complete frequency table; that is the most accurate reference for a specific formulation.

Beyond the GI effects, headache, fatigue and dizziness appear in clinical data for semaglutide more broadly. Injection-site reactions do not apply to tablets, though some people report mild oral discomfort. These effects are generally most pronounced when treatment begins or after a dose increase, and they tend to ease as the body adjusts. Taking the tablet exactly as directed (on an empty stomach first thing, with a small amount of plain water, waiting at least 30 minutes before eating or drinking anything else) reduces the severity for many people. Our page on oral semaglutide side effects covers the practical strategies prescribers typically suggest.

When should you seek medical help?

Most people on semaglutide tablets manage side effects without needing urgent care. But some symptoms need prompt medical attention. Call 999 or go to A&E for signs of a severe allergic reaction: sudden swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash that comes on quickly.

On 29 January 2026 the MHRA issued a Drug Safety Update specifically addressing acute pancreatitis with GLP-1 medicines. The warning symptom to know is severe, persistent stomach pain that spreads toward the back, sometimes with vomiting. Stop the medicine and get urgent help if that happens. Gallbladder problems (upper-right abdominal pain, jaundice, fever) also warrant a same-day GP call. Dehydration from repeated vomiting or diarrhoea can cause kidney problems; if you cannot keep fluids down for more than a day, seek advice.

For anything less acute (persistent nausea affecting daily life, symptoms that are not settling after two weeks, or concerns about a dose increase) speak to the prescriber who issued your prescription. Our prescribers discuss suitability, likely side effects, and how to manage them as a normal part of every consultation at nume's treatment assessment. Sorry, that should read: as a normal part of every consultation at the nume treatment assessment. The Yellow Card scheme also accepts reports from patients directly at yellowcard.mhra.gov.uk, you do not need to go through a doctor to report a suspected side effect.

Is there anything that makes semaglutide tablet side effects more or less likely?

A few factors consistently appear in clinical experience and the published trial data. People who rush through the titration schedule tend to report more intense GI symptoms; the dose steps exist partly to let the body adjust. Missing doses and then restarting, or taking the tablet with food, can also provoke stronger reactions. The question of whether anti-sickness medicines can be taken alongside is one that comes up regularly, the answer depends on which anti-emetic and your broader medication history, so it belongs in a prescriber conversation rather than a general guide.

People with a personal or family history of medullary thyroid cancer, pancreatitis or certain gastrointestinal conditions are typically not suitable candidates; that assessment happens at the consultation stage. Semaglutide tablets are not recommended during pregnancy, while breastfeeding, or for people actively trying to conceive. They are not licensed for under-18s. For a broader look at who these medicines are and are not suitable for, the safety assessment page goes into detail. If you have specific concerns about a medicine combination or pre-existing condition, our clinical team (including our lead prescriber) reviews every case individually before any prescription is issued.